Trial Profile
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Lifileucel (Primary) ; LN 145 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Ipilimumab; Nivolumab; Pembrolizumab
- Indications Adenocarcinoma; Head and neck cancer; Large cell carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 04 Apr 2024 Planned End Date changed from 1 Dec 2024 to 9 Aug 2029.
- 04 Apr 2024 Planned primary completion date changed from 1 Dec 2023 to 9 Aug 2029.
- 12 Sep 2023 Results (As of 21 Mar 2023) assessing efficacy and safety data for LN-145 autologous TIL cell therapy in combination with pembrolizumab in patients with ICI naive metastatic NSCLC presented at the 24th World Conference on Lung Cancer